Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Invested Capital (2020 - 2025)

Historic Invested Capital for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $976.6 million.

  • Janux Therapeutics' Invested Capital rose 4884.15% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year increase of 4884.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 19701.87% up from last year.
  • As of Q3 2025, Janux Therapeutics' Invested Capital stood at $976.6 million, which was up 4884.15% from $990.5 million recorded in Q2 2025.
  • Janux Therapeutics' Invested Capital's 5-year high stood at $1.0 billion during Q4 2024, with a 5-year trough of $299.5 million in Q2 2023.
  • Its 5-year average for Invested Capital is $542.0 million, with a median of $371.5 million in 2021.
  • As far as peak fluctuations go, Janux Therapeutics' Invested Capital skyrocketed by 260257.55% in 2021, and later plummeted by 1289.8% in 2023.
  • Over the past 5 years, Janux Therapeutics' Invested Capital (Quarter) stood at $366.3 million in 2021, then fell by 12.44% to $320.7 million in 2022, then grew by 7.36% to $344.3 million in 2023, then surged by 197.02% to $1.0 billion in 2024, then fell by 4.52% to $976.6 million in 2025.
  • Its last three reported values are $976.6 million in Q3 2025, $990.5 million for Q2 2025, and $1.0 billion during Q1 2025.